ArticleBritish journal of pharmacology1999
Inhibition of neuronal KV potassium currents by the antidepressant drug, fluoxetine.
Article in British journal of pharmacology, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 60 citations in OpenAlex.
- Paroxetine and fluconazole therapy for HIV-associated neurocognitive impairment: results from a double-blind, placebo-controlled trial.Journal of neurovirology · 2018Trial
- Fluoxetine Treatment in Epilepsy of Infancy with Migrating Focal Seizures Due to KCNT1 Variants: An Open Label Study.Annals of neurology · 2025Article
- Potassium channels in depression: emerging roles and potential targets.Cell & bioscience · 2024Review
- Inhibition of Ionic Currents by Fluoxetine in Vestibular Calyces in Different Epithelial Loci.International journal of molecular sciences · 2024Article
- KCNT2-Related Disorders: Phenotypes, Functional, and Pharmacological Properties.Annals of neurology · 2023Article
- Shuyu Capsules Relieve Premenstrual Syndrome Depression by Reducing 5-HTNeural plasticity · 2016Article
- Selective serotonin reuptake inhibitors facilitate ANO6 (TMEM16F) current activation and phosphatidylserine exposure.Pflugers Archiv : European journal of physiology · 2015Article
- Variants in Ion Channel Genes Link Phenotypic Features of Bipolar Illness to Specific Neurobiological Process Domains.Molecular neuropsychiatry · 2015Review
- Interaction of paroxetine with mitochondrial proteins mediates neuroprotection.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2015Article
- Effects of fluoxetine on protein expression of potassium ion channels in the brain of chronic mild stress rats.Acta pharmaceutica Sinica. B · 2015Article
- Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder?British journal of pharmacology · 2013Review
- Fluoxetine impairs GABAergic signaling in hippocampal slices from neonatal rats.Frontiers in cellular neuroscience · 2013Article
- Effects of dapoxetine on cloned Kv1.5 channels expressed in CHO cells.Naunyn-Schmiedeberg's archives of pharmacology · 2012Article
- Pulmonary vascular effects of serotonin and selective serotonin reuptake inhibitors in the late-gestation ovine fetus.American journal of physiology. Lung cellular and molecular physiology · 2011Article
- Reciprocal regulation of TREK-1 channels by arachidonic acid and CRH in mouse corticotropes.Endocrinology · 2011Article
- Activation of TREK currents by the neuroprotective agent riluzole in mouse sympathetic neurons.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2011Article
- AGN-2979, an inhibitor of tryptophan hydroxylase activation, does not affect serotonin synthesis in Flinders Sensitive Line rats, a rat model of depression, but produces a significant effect in Flinders Resistant Line rats.Neurochemistry international · 2009Article
- Antidepressants inhibit P2X4 receptor function: a possible involvement in neuropathic pain relief.Molecular pain · 2009Article
- Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine.British journal of pharmacology · 2005Article
- The voltage-gated potassium channel Kv1.3 regulates peripheral insulin sensitivity.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
1. The effect of the antidepressant drug, fluoxetine on neuronal delayed rectifier (KV) potassium (K) currents was investigated using perforated-patch whole-cell electrophysiological recording methods. 2. Fluoxetine was an effective inhibitor of KV currents in cerebellar granule neurons (CGNs) and also inhibited recombinant KV1.1 channels expressed in Chinese hamster ovary (CHO) cells. 3. Fluoxetine had an IC50 of 11 microM in CGNs but was slightly less potent on KV1.1 channels (IC50=55 microM). Interestingly, fluoxetine was a much more potent inhibitor of KV1.1 expressed in mammalian cells than has been found previously for the same homomeric channel expressed in Xenopus oocytes. 4. At concentrations that produced around 50% block, the shape of the KV currents in the presence of fluoxetine was simply scaled down when compared to control currents. 5. The effect of fluoxetine on KV currents in CGNs was neither voltage-dependent nor dependent on the channels being in their open state. Both of these observations suggest that fluoxetine does not act as a simple open channel blocking agent. 6. It is concluded that block of KV currents in mammalian neurons can occur at therapeutic levels of fluoxetine. This could lead to an increase in neuronal excitability and this effect may contribute to the therapeutic antidepressant action of fluoxetine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.